Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 4/20 | 0.50 |
| ▸ | GABRD | O14764 | 4/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.50 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.50 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.50 |
| ▸ | GABRA4 | P48169 | 4/20 | 0.50 |
| ▸ | GABRE | P78334 | 4/20 | 0.50 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.50 |
| ▸ | GABRG1 | Q8N1C3 | 4/20 | 0.50 |
| ▸ | GABRG3 | Q99928 | 4/20 | 0.50 |
| ▸ | GABRQ | Q9UN88 | 4/20 | 0.50 |
| ▸ | NNMT | P40261 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17362420 | 0.79 | SIRT6 (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2439314 | 0.75 | GABRP (0.43) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL31272529 | 0.75 | NNMT (0.70) | NNMTMKNK1MKNK2 | |
| SCHEMBL5847055 | 0.73 | IKBKB (0.50) | IKBKB | |
| SCHEMBL30259237 | 0.71 | IRAK4 (0.53) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL8564329 | 0.70 | ALDH1A1 (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL23852171 | 0.68 | — | — | |
| SCHEMBL5356192 | 0.68 | GABRP (0.63) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2031613 | 0.68 | — | — | |
| SCHEMBL29557324 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230467-A1 | 4,6-DIAMINONICOTINAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-09-22 | — | — | US | disclosed |
| US-20110230467-A1 | 4,6-DIAMINONICOTINAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-09-22 | — | — | US | disclosed |
| EP-2361902-A1 | 4,6-DIAMINONICOTINAMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2011-08-31 | — | — | EP | disclosed |
| EP-2361902-A1 | 4,6-DIAMINONICOTINAMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2011-08-31 | — | — | EP | disclosed |
| WO-2010058846-A1 | 4,6-DIAMINONICOTINAMIDE COMPOUND | アステラス製薬株式会社 (JP) | 2010-05-27 | — | — | WO | disclosed |
| US-6713484-B2 | FUSED RING PYRIMIDINE DERIVATIVES; LOW CYTOTOXICITY | WARNER-LAMBERT COMPANY | 2004-03-30 | — | — | US | disclosed |
| US-20030186987-A1 | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | BRIDGES ALEXANDER JAMES (US) | 2003-10-02 | — | — | US | disclosed |
| US-6521620-B1 | Suppressing tumors, especially breast cancers; antiproli-ferative agents; arthritis, vascular restenosis, psoriasis and angiogenesis; extremely low cytotoxicity | WARNER-LAMBERT COMPANY | 2003-02-18 | — | — | US | disclosed |
| US-6455534-B2 | ANTIPROLIVERATIVE, -CARCINOGENIC AND -TUMOR AGENTS; MITOGENESIS-ACTIVATED PROTEIN KINASE INHIBITORS; NONCYTOTOXIC; BINDING WITH HIGH AFFINITY AT THE ADENOSINE TRIPHOSPHATE BINDING SITE OF THE KINASES | WARNER-LAMBERT COMPANY | 2002-09-24 | — | — | US | disclosed |
| US-20010027197-A1 | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | BRIDGES ALEXANDER JAMES (US) | 2001-10-04 | — | — | US | disclosed |
| US-6265410-B1 | ANTICARCINOGENIC AGENTS | WARNER-LAMBERT COMPANY | 2001-07-24 | — | — | US | disclosed |
| US-6084095-A | INCLUDING 6-AMINO-4-(3-BROMOANILINO)PYRIDO(3,2-D)PYRIMIDINE; 4-(3-BROMOANILINO)-6-METHYLAMINOPYRIDO (3,2-D)PYRIMIDINE; AND 4-(3-BROMOANILINO)-6-METHYLAMINOPYRIDO(3,2-D)PYRIMIDINE; USEFUL IN TREATING PROLIFERATIVE DISEASES SUCH AS CANCER | WARNER-LAMBERT COMPANY (US) | 2000-07-04 | — | — | US | disclosed |
| US-5654307-A | ANTICARCINOGENIC AGENTS, ANTIARTHRITIC AGENT, SKIN DISORDERS | WARNER-LAMBERT COMPANY (US) | 1997-08-05 | — | — | US | disclosed |
| EP-0742717-A1 | BICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1996-11-20 | — | — | EP | disclosed |
| WO-1995019774-A1 | BICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1995-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230467-A1 | 4,6-DIAMINONICOTINAMIDE COMPOUND | JAK3, JAK2, JAK1 | GABRP 3948/4885GABRD 3468/4885GABRA1 3228/4885 |
| US-20010027197-A1 | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | EGFR, ERBB2, ERBB3 | GABRP 1336/4885GABRD 1716/4885GABRA1 1514/4885 |
| US-20030186987-A1 | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | EGFR, ERBB2, ERBB3 | GABRP 2049/4885GABRD 1881/4885GABRA1 1793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.